Arlinda Lee
Stock Analyst at Canaccord Genuity
(1.69)
# 2,108
Out of 4,414 analysts
28
Total ratings
48.33%
Success rate
16.52%
Average return
Main Sectors:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems | Maintains: Buy | $18 → $21 | $5.40 | +288.89% | 3 | Sep 7, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $20 → $10 | $1.11 | +804.98% | 1 | Apr 5, 2022 | |
| BNTX BioNTech SE | Maintains: Buy | $450 → $300 | $89.95 | +233.52% | 5 | Apr 5, 2022 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $25 → $6 | $1.65 | +263.64% | 4 | Mar 16, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $45 → $36 | $41.43 | -13.11% | 1 | Mar 7, 2022 | |
| DCPH Deciphera Pharmaceuticals | Downgrades: Hold | n/a | $25.36 | - | 1 | Nov 8, 2021 | |
| CELC Celcuity | Initiates: Buy | n/a | $16.30 | - | 1 | Oct 8, 2021 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | n/a | $53.81 | - | 1 | Aug 16, 2021 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | n/a | $24.20 | - | 1 | Jul 13, 2021 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | n/a | $43.30 | - | 3 | Jul 2, 2020 | |
| BDTX Black Diamond Therapeutics | Initiates: Buy | n/a | $5.90 | - | 1 | Feb 24, 2020 | |
| CARA Cara Therapeutics | Maintains: Buy | n/a | $0.76 | - | 2 | Aug 15, 2018 | |
| AKTX Akari Therapeutics, | Maintains: Buy | n/a | $1.70 | - | 1 | Mar 29, 2018 | |
| KPTI Karyopharm Therapeutics | Maintains: Buy | n/a | $1.08 | - | 1 | Mar 12, 2018 | |
| HALO Halozyme Therapeutics | Maintains: Buy | n/a | $39.30 | - | 1 | Nov 8, 2017 | |
| BPMC Blueprint Medicines | Maintains: Buy | n/a | $94.86 | - | 1 | Sep 20, 2017 |
Delcath Systems
Sep 7, 2023
Maintains: Buy
Price Target: $18 → $21
Current: $5.40
Upside: +288.89%
X4 Pharmaceuticals
Apr 5, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $1.11
Upside: +804.98%
BioNTech SE
Apr 5, 2022
Maintains: Buy
Price Target: $450 → $300
Current: $89.95
Upside: +233.52%
Nektar Therapeutics
Mar 16, 2022
Maintains: Buy
Price Target: $25 → $6
Current: $1.65
Upside: +263.64%
Rhythm Pharmaceuticals
Mar 7, 2022
Maintains: Buy
Price Target: $45 → $36
Current: $41.43
Upside: -13.11%
Deciphera Pharmaceuticals
Nov 8, 2021
Downgrades: Hold
Price Target: n/a
Current: $25.36
Upside: -
Celcuity
Oct 8, 2021
Initiates: Buy
Price Target: n/a
Current: $16.30
Upside: -
CRISPR Therapeutics AG
Aug 16, 2021
Maintains: Buy
Price Target: n/a
Current: $53.81
Upside: -
Bicycle Therapeutics
Jul 13, 2021
Maintains: Buy
Price Target: n/a
Current: $24.20
Upside: -
Ultragenyx Pharmaceutical
Jul 2, 2020
Maintains: Buy
Price Target: n/a
Current: $43.30
Upside: -
Black Diamond Therapeutics
Feb 24, 2020
Initiates: Buy
Price Target: n/a
Current: $5.90
Upside: -
Cara Therapeutics
Aug 15, 2018
Maintains: Buy
Price Target: n/a
Current: $0.76
Upside: -
Akari Therapeutics,
Mar 29, 2018
Maintains: Buy
Price Target: n/a
Current: $1.70
Upside: -
Karyopharm Therapeutics
Mar 12, 2018
Maintains: Buy
Price Target: n/a
Current: $1.08
Upside: -
Halozyme Therapeutics
Nov 8, 2017
Maintains: Buy
Price Target: n/a
Current: $39.30
Upside: -
Blueprint Medicines
Sep 20, 2017
Maintains: Buy
Price Target: n/a
Current: $94.86
Upside: -